The legal action, filed by Hagens Berman Sobol Shapiro LLP, targets a class period spanning May 13, 2025, to February 19, 2026. Plaintiffs allege that executives repeatedly championed the trial’s three-year follow-up structure as sufficient to prove a reduction in late-stage cancer diagnoses, while allegedly obscuring internal data that suggested the timeline was inadequate. The company’s stock price plummeted from $101.53 to $50.21 on February 20, 2026, after GRAIL admitted the study failed its primary endpoint and conceded that a longer follow-up period likely should have been implemented.

Reed Kathrein, the Hagens Berman partner heading the case, stated the firm is investigating exactly when leadership recognized the discrepancy between their public projections and the study's actual limitations. Beyond the pending litigation, the firm is encouraging whistleblowers with non-public information regarding these clinical disclosures to come forward. Investors who acquired common stock during the specified period and incurred substantial losses are advised to contact legal counsel before the court-mandated August deadline to participate in the case.